With $30 Million Series B In Hand, Elevation Prepares To Take Inhalable COPD Drug Up To Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
The two-tranche financing, backed 50% by new investor Novo Ventures, will enable the private firm to evaluate early partnering opportunities from a position of financial stability.
You may also be interested in...
Sunovion To Purchase Elevation And Phase II Drug/Device Combo For COPD
Earlier than anticipated exit for Elevation means less dilution for its venture capital backers, who had provided $30 million in Series B funds this past January.
Deals Of The Week: Sunovion/Elevation, Janssen/Genmab, Alnylam/Monsanto
With Roche’s Pascal Soriot set to become AstraZeneca’s CEO on Oct. 1, Soriot’s success in merging Genentech into Roche may open up AZ’s business development strategy to large-scale M&A.
Sunovion To Purchase Elevation And Phase II Drug/Device Combo For COPD
Earlier than anticipated exit for Elevation means less dilution for its venture capital backers, who had provided $30 million in Series B funds this past January.